

HOUSE SUMMARY OF SENATE AMENDMENTS**HB 117****2022 Regular Session****Echols**

DRUGS/PRESCRIPTION: Provides relative to prescribing, administering, and dispensing of drugs for off-label use

Synopsis of Senate Amendments

1. Stipulates that nothing in proposed law shall be construed to restrict, preclude, or prohibit the state health agency or any state licensing board from taking all actions necessary to protect the public health, safety, and welfare from harm or abuse due to prescription drug off-label use.

Digest of Bill as Finally Passed by Senate

Present law provides for licensure and regulation by the state of various types of healthcare professionals.

Proposed law retains present law and stipulates that neither the La. Dept. of Health (LDH) nor any healthcare professional licensing board or commission shall prohibit or restrict the prescribing, administering, or dispensing for an off-label use a drug that has been approved for a specific use by the U.S. Food and Drug Administration (FDA).

Proposed law defines "off-label use", for purposes of proposed law, as the use of a prescription drug for an indication for which it has not been approved by the FDA or the use of such drug in an age group, dosage, or route of administration that has not been approved by the FDA.

Proposed law stipulates that nothing in proposed law shall be construed to restrict, preclude, or prohibit LDH or any healthcare professional licensing board or commission from taking all actions necessary to protect the public health, safety, and welfare from harm or abuse due to prescription drug off-label use.

(Adds R.S. 37:1704)